Following the 2nd infographic of the series about Heart Failure, this one come to explain the diagnosis, stratification risk & treatment options for chronic HF patients NYHA 2-4 class

1. Class I Class II Class III Class IV
How to Diagnose Heart Failure?
Let’s foSTeR a life-lONG
healthy heart3
2- Blood Tests
A strain on the heart or other
organs such as the kidneys and
liver
q Marked limitation in
activity due to
symptoms, even
during less-than-
ordinary activity.
q Mild symptoms
q slight limitation
during ordinary
activity.
q Severe limitations.
Experiences
symptoms even
while at rest. Mostly
bedbound patients.
q No symptoms
q No limitation in
ordinary
physical activity
The New York Heart Association (NYHA)
classifying the extent of heart failure
Verquvo
Vericiguat
Entresto
(sacubitril/valsartan)
Pre-
Diagnosis
Diagnosis &
Initial
Treatment
Worsening
HF Event
Discharge
DAPA-HF, FDA Approved 20
EMPEROR, Data readout
Aug-20
PARADIGM-HF, FDA Approved Y15
VICTORIA, Priority Review Jan - 21
7- MRI
Heart's structure & blood
flows through heart and
major vessels.
9- MUGA
Heart muscle performance
for blood supply & heart's
chambers function
3- Stress Test
Heart responds to the
stress, Type & level of
appropriate exercise 4- Chest X-ray
Heart structure & congestion in
the lungs
6- ECG
Previous heart attack, thickness
of LV & Heart rhythm
5- Echo
How thick the heart muscle
How well the heart pumps.
8- Cardiac Catherization
Blockages/narrowing in the
coronary arteries
1- Physical Examination
Annual
Mortality
Ph.3 trial, Approval status
Farxiga
Dapagliflozin
Jardiance
empagliflozin
Treatment options
For HFrEF patient with (NYHA II-IV)
Beta
Blockers
ACEi/
ARB/ MRA
Diuretics
sGC modulator
ARNi
CMA
SGLT-2i
CMA: cardiac myosin activators
ARNi: angiotensin receptor-neprilysin inhibitor
SGLT-2i: Sodium/glucose cotransporter-2 inhibitors
sGC: soluble guanylate cyclase
ACEi: Angiotensin converting enzyme inhibitor
ARB: Angiotensin receptor block
MRA: Mineralocorticoid receptor antagonist
Company
logo
Trade name
Generic name
https://manual.jointcommission.org/releases/TJC2016A/DataElem0439.html#:~:text=NYHA%20Classification%20%2D%20The%2
0Stages%20of,slight%20limitation%20during%20ordinary%20activity.
https://www.webmd.com/heart-disease/heart-failure/news/20200506/fda-approves-diabetes-drug-for-type-of-heart-failure
https://www.businesswire.com/news/home/20200730005445/en/Empagliflozin-meets-primary-endpoint-reducing-risk-
cardiovascular
http://www.pmlive.com/pharma_news/trial_of_amgen,_serviers_heart_failure_drug_clears_interim_check_1327107
https://www.fiercebiotech.com/biotech/fda-puts-merck-s-heart-failure-drug-priority-review-
Acute/Chronic therapy & Symptoms reliefEmerging Therapies
21
By:- Mohamed Ibrahim Seddik
For other infographic,
Click
GALACTIC-HF, Top line data
by End 21
Omecamtiv